Trials / Terminated
TerminatedNCT00319930
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Pharmacodynamic Study of Intravenously Administered CNF1010 (17-(Allylamino)-17-demethoxy-geldanamycin [17-AAG]) in Patients With ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia (CLL)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CNF1010 (17-AAG) |
Timeline
- Start date
- 2005-05-01
- Completion
- 2007-05-01
- First posted
- 2006-04-27
- Last updated
- 2010-03-08
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00319930. Inclusion in this directory is not an endorsement.